Insights › Market reaction

Why Halozyme Therapeutics (HALO) Stock Fell 6.22% in 10 Minutes After Q3 Earnings on Nov 5, 2026

Adjusted EPS of $2.39 came in above the $2.35 estimate; revenue of $492.97 million came in above the $491.56 million estimate.

Published in ET: Feed time in ET: Earnings HALO -6.22% in 10 min after the headline
  • HALO fell 6.22% in the 10 minutes after the 16:06:44 ET headline, from $121.93 to $114.35.
  • 20,276 shares changed hands in those 10 minutes.
  • The headline crossed in after-hours trading, 6 minutes after the 4:00 ET close.
HALO Why Halozyme Therapeutics (HALO) Stock Fell 6.22% in 10 Minutes After Q3 Earnings on Nov 5,
MoveSurge publish 16:06:44 ET
MoveSurge publish
16:06:44 ET
124.38 120.70 116.91 113.23 114.25 16:04 16:06 16:26
Real 1-minute OHLC candles around publish time. Chart times are New York ET; validated market data captured by MoveSurge.

Reaction by asset (real prices)

Asset2m beforeAt release+1m+10m+1m %+10m %
HALO 121.93 121.93 115.03 114.35 -5.66% -6.22%

Halozyme Therapeutics (HALO) shares fell 6.22% in the 10 minutes after its Q3 results reached the MoveSurge news feed at 16:06:44 ET on Thursday, November 5, 2026. Adjusted EPS of $2.39 came in above the $2.35 estimate; revenue of $492.97 million came in above the $491.56 million estimate.

HALO in the first 10 minutes

The line that crossed at 16:06:44 ET: “HALO Q3: adj. EPS 2.39 vs 2.35 est; revenue USD 492.97mln vs USD 491.56mln est”

From a reference price of $121.93 just before the headline, the stock was down 5.66% after one minute and down 6.22%, at $114.35, after 10 minutes. The first-minute move held. 20,276 shares changed hands in those 10 minutes. The headline crossed in after-hours trading, 6 minutes after the 4:00 ET close.

Halozyme Therapeutics Q3 results against estimates

MeasureReportedEstimateResult
Adjusted EPS$2.39$2.35Beat
Revenue$492.97 million$491.56 millionBeat

Halozyme Therapeutics at a glance

SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Market value$14.79 billion (as of Nov 5, 2026)

Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.

How did Halozyme Therapeutics stock react to its Q3 earnings on November 5, 2026?

The stock fell 6.22% in the 10 minutes after its Q3 results crossed at 16:06:44 ET. Adjusted EPS of $2.39 came in above the $2.35 estimate; revenue of $492.97 million came in above the $491.56 million estimate.

How far did HALO move after the headline?

From $121.93 just before the headline to $114.35 10 minutes later, a -6.22% move.

Sources

Never miss the next market-moving story

Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.

Go live — 7 days for $29 Watch live headlines -- free
See live news
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Core market coverageEquities, macro, currencies and commodities Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Go real time View the live feed Subscription renews automatically. Cancel before renewal. Information only—no trade calls.